1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • L-Mind: A safety and efficacy analysis of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving treatment for at least 2 years
    Meeting Abstract

    Duell, J.; Jurczak, W.; Liberati, A. M.; Halka, J.; Pena Carbó, E.; Abrisqueta Costa, P.; Maddocks, K. J.; Dreyling, M.; Rosenwald, A.; Bakuli, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the BTK/FLT3 inhibitor luxeptinib in patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Samaniego, F.; Sadiq, A. A.; Mahadevan, D.; Koontz, M. Z.; Villasboas, J. C.; Burke, J. M.; Reid, E. G.; Cherry, M.; Melear, J.; Priego, V.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients with diffuse large B-cell lymphoma (DLBCL) treated with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in the phase III POLARIX study
    Meeting Abstract

    Friedberg, J. W.; Thompson, C. A.; Trněný, M.; Morschhauser, F.; Salles, G.; Reagan, P. M.; Hertzberg, M.; Smolewski, P.; Zhang, H.; Thieblemont, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: Characterization of a large cohort with long-term outcomes shows disparate outcomes by body region involvement
    Meeting Abstract

    Stuver, R.; Ghione, P.; Ganesan, N.; Noor, S.; Imber, B. S.; Pulitzer, M.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Pooled safety analysis from phase I-III studies for patients with hematological malignancies treated with the PI3K inhibitor copanlisib
    Meeting Abstract

    Zinzani, P. L.; Özcan, M.; Capra, M.; Santoro, A.; Panayiotidis, P.; Bouabdallah, K.; Jurczak, W.; Phelps, C.; Hiemeyer, F. J. R.; Soler, L. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Pharmacodynamics and biomarker correlates of imvotamab (IGM-2323), the first-in-class CD20xCD3 bispecific IgM antibody with dual mechanisms of action, in patients with advanced B cell malignancies
    Meeting Abstract

    Hernandez, G. H.; So, J.; Logronio, K. A.; Kotturi, M. F.; Kim, W. S.; Armand, P.; Cheah, C. Y.; Gopal, A. K.; Flinn, I. W.; Gregory, G. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Validation of a cell-free DNA NGS assay for hematological malignancies
    Meeting Abstract

    Gedvilaite, E.; DiNapoli, S.; Spence, C.; Diosdado, M. S.; Razumova, A.; Bowman, A. S.; Tsui, D. W. Y.; Salles, G.; Batlevi, C. L.; von Keudell, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genetic Alterations of CREBBP are associated with radiosensitivity in follicular lymphoma
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E. S.; Lee, J.; Fregonese, B.; Tringale, K. R.; Hubbeling, H.; Sarkar, R.; Ma, J.; Seshan, V.; Joffe, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • LymphGen classification of diffuse large B-cell lymphoma in a cohort of adolescent and young adult (AYA) patients
    Meeting Abstract

    Cabal, A.; Zhu, M.; Uppal, M.; Joffe, E.; Batlevi, C. L.; Matasar, M. J.; Okwali, M.; Dogan, A.; Zelenetz, A. D.; Salles, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • BCL6 rearranged indolent B-cell lymphomas show mutational profile similar to marginal zone lymphomas
    Meeting Abstract

    Galera, P. K.; Qualls, D.; Aypar, U.; Kostrzewa, C.; Zhu, M.; Baik, J.; Seshan, V.; Salles, G.; Dogan, A.
    Blood (2022)

    Fulltext@MSK | Save